Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Al Khanbashi, Manal ^a   Caramuta, Stefano ^b   Alajmi, Adil M ^a   Al Haddabi, Ibrahim ^a   Al Riyami, Marwa ^a   Lui, Weng Onn ^b   Al Moundhri, Mansour S ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; MICRORNA; MICRORNA 205; MICRORNA 21; MICRORNA 3200; MICRORNA 451; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TISSUE LEVEL; TREATMENT OUTCOME; UPREGULATION; ADJUVANT CHEMOTHERAPY; BLOOD; BREAST NEOPLASMS; CANCER STAGING; DNA MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TAXOIDS; TRASTUZUMAB;

EID: 84963767546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152032     Document Type: Article

References (46)

1. Hutchinson L: Breast cancer: Challenges, controversies, breakthroughs. Nature Reviews Clinical Oncology 2010, 7:669-670. doi:10.1038/nrclinonc.2010.192 PMID: 21116236
2. Rashish BA, Dinshaw Ketayun, Jalali Rakesh: Management of locally advanced breast cancer: Evolution and current practice. Journal of Cancer Research and Therapeutics 2005, 1(1):21-30. PMID: 17998621
3. Lee MC, Newman LA: Management of Patients with Locally Advanced Breast Cancer. Surgical Clinics of North America 2007, 87(2):379-398. PMID: 17498533
4. Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, Rosenman J, Ollila DW, Graham M: Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma: Effective Clinical Downstaging Allows Breast Preservation and Predicts Outstanding Local Control and Survival. ANNALS OF SURGERY 2002, 236(3):295-303. PMID: 12192316
5. de Planell-Saguer MariÃn, Rodicio MC: Detection methods for microRNAs in clinic practice. Clinical biochemistry 2013, 46(10-11):869-878. doi:10.1016/j.clinbiochem.2013.02.017 PMID: 23499588
6. Molnár V, Tamási V, Bakos B, Wiener Z, Falus A: Changes in miRNA expression in solid tumors: An miRNA profiling in melanomas. Seminars in Cancer Biology 2008, 18(2):111-122. doi:10.1016/j. semcancer.2008.01.001 PMID: 18296065
7. Fabbri M, Croce C, Calin G: MicroRNAs. The Cancer Journal 2008, 14(1):1-6. doi:10.1097/PPO. 0b013e318164145e PMID: 18303474
8. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(9):2999-3004. PMID: 14973191
9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K etal: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences 2002, 99(24):15524-15529.
10. Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M et al: MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research 2005, 65(16):7065-7070. PMID: 16103053
11. Wang B, Li JD, Sun M, Sun LH, Zhang XY: MiRNA Expression in Breast Cancer Varies with Lymph Node Metastasis and Other Clinicopathologic Features. IUBMB LIFE 2014, 66(5):371-377. doi:10. 1002/iub.1273 PMID: 24846313
12. Mattie M, Benz C, Bowers J, Sensinger K, Wong L, Scott G, Fedele V, Ginzinger D, Getts R, Haqq C: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24. PMID: 16784538
13. van Schooneveld E, Wildiers H, Vergote I, Vermeulen P, Dirix L, Van Laere S: Dysregulation of micro-RNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Research 2015, 17(1):21.
14. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ: Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. ANNALS OF SURGERY 2010, 251(3):499-505. doi:10.1097/SLA.0b013e3181cc939f PMID: 20134314
15. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DSB: Direct Serum Assay for Micro-RNA-21 Concentrations in Early and Advanced Breast Cancer. Clinical Chemistry 2011, 57(1):84-91. doi:10.1373/clinchem.2010.151845 PMID: 21036945
16. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA-A PUBLICATION OF THE RNA SOCIETY 2008, 14(11):2348-2360.
17. Zhu W, Qin W, Atasoy U, Sauter E: Circulating microRNAs in breast cancer and healthy subjects. BMC Research Notes 2009, 2(1):89.
18. Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic Oncology 2010, 119(3):586-593. doi:10. 1016/j.ygyno. 2010.07.021 PMID: 20801493
19. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale A-L, Santarpia L: A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research 2015, 21(5):1207-1214. doi:10.1158/1078-0432. CCR-14-2011 PMID: 25547678
20. Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010.
21. Khokher Samina QMU, C NA: Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer. Asian Pacific Journal of Cancer Prevention 2012, 13(7):3213-3218. PMID: 22994736
22. Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R: Residual cancer burden in locally advanced breast cancer: a superior tool. Current Oncology 2008, 15(6):271-278. PMID: 19079627
23. Burgos KL, Javaherian A, Bomprezzi R, Ghaffari L, Rhodes S, Courtright A, Tembe W, Kim S, Metpally R, Van Keuren-Jensen K: Identification of extracellular miRNA in human cerebrospinal fluid by nextgeneration sequencing. RNA 2013, 19(5):712-722. doi:10.1261/rna.036863.112 PMID: 23525801
24. Xiong Y, Chen S, Liu L, Zhao Y, Lin W, Ni J: Increased Serum MicroRNA-155 Level Associated with Nonresponsiveness to Hepatitis B Vaccine. Clinical and Vaccine Immunology: CVI 2013, 20(7):1089-1091. doi:10.1128/CVI.00044-13 PMID: 23637039
25. Hu Z, Dong J, Wang L-E, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q etal: Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 2012, 33(4):828-834. doi:10.1093/carcin/bgs030 PMID: 22298638
26. Peltier HJ, Latham GJ: Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14(5):844-852. doi:10.1261/rna.939908 PMID: 18375788
27. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH: Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing. PLoS ONE 2012, 7(4):e34150. doi:10.1371/journal. pone.0034150 PMID: 22529906
28. Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, Troncone G, De Stefano A, Pepe S, De Placido S et al: Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. BioMed Research International 2014, 2014:8.
29. Lee DY, Deng Z, Wang C-H, Yang BB: MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(51):20350-20355. PMID: 18077375
30. Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, Van Laere SJ: Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 2010, 103(4):532-541. doi:10.1038/sj.bjc.6605787 PMID: 20664596
31. Vageli D, Doukas SG, Kerenidi T, Koukoulis GK, Gourgoulianis KI, Daniil Z: Correlation of miR-422a, miR-21 and miR-155 analysis with hMSH2andhMLH1 mRNA expression profiles in non-small cell lung carcinomas and their adjacent normal tissues. European Respiratory Journal 2013, 42(Suppl57).
32. Wang G, Wang L, Sun S, Wu J, Wang Q: Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females. Annals of Laboratory Medicine 2015, 35(2):226-232. doi:10.3343/alm.2015.35.2.226 PMID: 25729725
33. Kang WK, Lee JK, Oh ST, Lee SH, Jung CK: Stromal expression of miR-21 in T3-4a colorectal cancer is an independent predictor of early tumor relapse. BMC Gastroenterology 2015, 15:2. doi:10.1186/s12876-015-0227-0 PMID: 25609245
34. Pan X, Wang R, Wang Z-X: The Potential Role of miR-451 in Cancer Diagnosis, Prognosis, and Therapy. Molecular Cancer Therapeutics 2013, 12(7):1153-1162. doi:10.1158/1535-7163. MCT-12-0802 PMID: 23814177
35. Majid S, Dar AA, Saini S, Chen Y, Shahryari V, Liu J, Zaman MS, Hirata H, Yamamura S, Ueno K etal: Regulation of Minichromosome Maintenance Gene Family by MicroRNA-1296 and Genistein in Prostate Cancer. Cancer Research 2010, 70(7):2809-2818. doi:10.1158/0008-5472CAN-09-4176 PMID: 20332239
36. Yang X-W, Shen G-Z, Cao L-Q, Jiang X-F, Peng H-P, Shen G, Chen D, Xue P: MicroRNA-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of FOXO1. BMC Cancer 2014, 14(1):909.
37. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, Piazza S, Cappelletti V, Daidone M, Agami R etal: Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013, 12(11):1679-1687. doi:10.4161/cc.24757 PMID: 23656790
38. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Molecular Cancer Therapeutics 2008, 7(7):2152-2159. doi:10.1158/1535-7163. MCT-08-0021 PMID: 18645025
39. Freres P, Josse C, Bovy N, Boukerroucha M, Struman I, Bours V, Jerusalem G: Neoadjuvant chemotherapy in breast cancer patients induces expression of miR-34a and miR-122. European Journal of Cancer 2014, 50(Journal Article):53-54.
40. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH: Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Molecular Oncology 2013, 8(1):59-67. doi:10.1016/j.molonc.2013.09.001 PMID: 24119443
41. Ng EKO, Li R, Shin VY, Jin HC, Leung CPH, Ma ESK, Pang R, Chua D, Chu K-M, Law WLetal: Circulating microRNAs as Specific Biomarkers for Breast Cancer Detection. PLoS ONE 2013, 8(1):e53141. doi:10.1371/journal.pone.0053141 PMID: 23301032
42. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM: Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Research 2009, 37(8):2584-2595. doi:10.1093/nar/gkp117 PMID: 19264808
43. Xu H, Mei Q, Shi L, Lu J, Zhao J, Fu Q: Tumor-suppressing effects of miR451 in human osteosarcoma. Cell biochemistry and biophysics 2014, 69(1):163-168. doi:10.1007/s12013-013-9783-5 PMID: 24218283
44. To K: MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. Journal of Biomedical Science 2013, 20(1):99.
45. Kalniete D, Nakazawa-Miklasevica M, Strumfa I, Abolins A, Irmejs A, Trofimovics G, Gardovskis J, Miklasevics E: MicroRNA Expression in Different Sybtypes of Breast Cancer. Acta Chirurgica Latviensis 2013, 13(1):7-12.
46. Ippolito E, Iorio M: MicroRNAs and Triple Negative Breast Cancer. International Journal of Molecular Sciences 2013, 14(11):22202-22220. doi:10.3390/ijms141122202 PMID: 24284394